Genetic risk factors of cytolysis syndrome in the treatment of recrudescence of chronic cardiovascular diseases

Aim. To assess the clinical, biochemical, and genetic risk factors for the development of hepatocyte cytolysis syndrome in patients with a combination of fatty liver disease and recrudescence of chronic cardiovascular pathology.
Material and methods. The study included 74 patients with chronic cardiovascular disease (coronary heart disease, chronic heart failure, hypertension) treated in the cardiology department of the Central Clinical Hospital of the Siberian Branch of Russian Academy of Sciences with a normal baseline transaminase level (AST and ALT); 12 of them have increasing of transaminase level on 10-12 days. All patients underwent therapeutic and diagnostic procedures in accordance with the medical standards in Russian Federation. Genotyping of polymorphic loci of the genes of the cytochrome P450 family was carried out using real-time polymerase chain reaction (PCR).
Results. There was no significant correlation between cytolysis syndrome and phenotypic characteristics: gender, age, body mass index. A positive correlation of fatty liver disease with abdominal obesity and body mass index was confirmed. There was no significant correlation between cytolysis syndrome and clinical and biochemical risk factors: comorbidity and lipid profile. The presence of minor minor allele of cytochrome P-450 — CYP2C9, CYP2D6, CYP2C19 genes in a patient with fatty liver disease increases the risk of cytolysis syndrome during CVD therapy.
Conclusion. Pharmacogenetic testing of polymorphic variants of cytochrome P-450 — CYP2C9, CYP2D6, CYP2C19 genes is advisable to recommend to patients with cardiovascular diseases and high-risk of liver disorders for a personalized approach to therapy.

1. Mengoli M, Parmeggiani D, Mengoli MC. Drug-induced hepatotoxicity: clinical and biochemical features of 26 patients and a review of the literature. Recenti Prog Med. 2011,Jun;102(6):253-60. doi:101701/893.9843.

2. Van Wagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016,Jun;15(2):75-85. doi:10.1007/s11901-016-0295-9.

3. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol.Hepatol. 2009 Feb;7(2):234-8. doi:10.1016/j.cgh.2008.11.005.

4. Cazanave S, Gores G. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol. 2010;5(1):71-85 doi:10.2217/clp.09.85.

5. Kodama Y, Brenner DA. C-Jun N-terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease: multiple roles in multiple steps. Hepatology. 2009;49(1):6- 8. doi:10.1002/hep.22710.

6. Shulpekova YuO. Pathogenic role of lipids in non-alcoholic fatty liver disease. RJGHC. 2012; 22(1):45-56. (In Russ.).

7. Introduction to Hepatology: a guide. Schiff YR, Sorrel MF, Maddrey US. A translation from English. Ed. Ivashkin VT, Bauerova AO, Maevskaya MV. 2011. 704 p. (In Russ.). ISBN 978-5-9704-1969-4.

8. Ivashkin VT, Mayevskaya MV, Pavlov ChS, et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association RJGHC. 2016;26(2):24-42 (In Russ.).